STOCKHOLM, March 2 (Reuters) - Swedish in vitro
fertilisation (IVF) technology firm Vitrolife VITR.ST said on
Monday it expected sales in Asia, which accounted for about a
quarter of revenue in 2019, to fall 30% in the first three
months of 2020 due to the coronavirus outbreak.
Vitrolife, a maker of devices for assisted reproduction,
said IVF clinics in China had started to receive patients again
after being closed for several weeks due to the outbreak.
"But the intake of patients is very low, which is why
Vitrolife estimates that sales in China will be significantly
lower than normal also in the remaining part of the quarter,"
CEO Thomas Axelsson said in a statement.
The company, which also said demand had been lower than
usual in neighbouring markets outside China, said it believed
the vast majority of patients scheduled for IVF treatments in
the first quarter would complete them at a later date.
(Reporting by Johannes Hellstrom; Editing by David Clarke)
((johannes.hellstrom@thomsonreuters.com; +46850242388; Reuters
Messaging: johannes.hellstrom.reuters.com@reuters.net))